COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care?

— News, features, and commentary about cancer-related issues

MedicalToday
Cancer cells with OncoBreak in the center.

Oncologists' with CAR T-cell therapy and its high cost has increased. (Cardinal Health)

About 40% of women reported after risk-reducing salpingo-ovariectomy, and sleep problems persisted long-term in 18%. (Gynecologic Oncology)

An Israeli study showed that 90% of patients on active cancer treatment obtained after a second dose of the Pfizer/BioNTech vaccine. (JAMA Oncology)

Lipac Oncology announced that the locally administered taxane, TSD-001 (LIPax), led to a of 83% in nonmuscle invasive bladder cancer.

Naveris announced that a saliva (HPV) identified viral DNA in 44 of 46 patients with HPV-related oropharyngeal cancer, suggesting potential as a test for early diagnosis.

A biotech startup has attracted major investor support for an ambitious plan to develop drugs that target , beginning with acute myeloid leukemia. (Endpoints News)

During treatment for a heart attack, a patient learned he had inoperable colon cancer and optimistically asked how long the treatment would continue. (Journal of Clinical Oncology - Art of Oncology)

A review of a National Cancer Institute database showed that only 11% of 3,450 U.S. patients had an and its role in cancer treatment. (Cancer Epidemiology Biomarkers & Prevention)

With the aid of machine learning techniques (artificial intelligence), a potential moved a step closer to reality. (London School of Hygiene & Tropical Medicine)

Men with high-risk prostate cancer had better survival if they received as compared with deferred (salvage) radiotherapy. (Journal of Clinical Oncology, Brigham and Women's Hospital)

Remote monitoring of selected patients receiving cancer treatment may , according to a study of patients with cancer and COVID-19. (Mayo Clinic)

The adverse effect of COVID-19 on cancer research has persisted into 2021, as the U.S. led all other countries in , particularly phase II trials. (GlobalData)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined in 2007.